Cytokinetics (CYTK) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TG Therapeutics (TGTX) has outperformed Cytokinetics (CYTK) over the past year, gaining 49.2% versus a gain of 2.0%. Over five years, CYTK leads with a +68.1% price change compared with +60.1% for TGTX. Cytokinetics is the larger company by market cap ($8.62 billion vs $8.17 billion), about 1.1 times the size.
TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYTK | TGTX |
|---|---|---|
| Share price | $62.01 | $53.34 |
| Market cap | $8.62B | $8.17B |
| 1-day change | +1.46% | +0.74% |
| YTD return | -2.41% | +78.93% |
| 1-year return | +1.96% | +49.20% |
| 5-year return | +68.09% | +60.13% |
| P/E ratio (TTM) | — | 19.40 |
| Forward P/E | — | 19.70 |
| EPS (TTM) | $-7.22 | $2.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $88.04M | $616.29M |
| Revenue growth (YoY) | +376.56% | +87.32% |
| Net income (latest FY) | $-784.96M | $447.18M |
| Gross margin | — | 83.66% |
| Operating margin | -695.44% | 20.01% |
| Net margin | -891.60% | 72.56% |
| 52-week high | $88.31 | $59.30 |
| 52-week low | $54.30 | $26.76 |
| Distance from 52-week high | -29.78% | -10.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.23% | +30.69% |
| Average volume | 1.97M | 2.01M |
| Shares outstanding | 139.02M | 153.08M |
| Employees | 673 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TGTX has outperformed CYTK by 47.2 percentage points over the past year.
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +87.32%).
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
CYTK vs TGTX FAQ
Which is bigger, Cytokinetics or TG Therapeutics?
Cytokinetics (CYTK) is larger, with a market capitalization of $8.62B compared with $8.17B for TG Therapeutics (TGTX).
Which stock has performed better over the past year, CYTK or TGTX?
TGTX returned +49.20% over the past 12 months, compared with +1.96% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Cytokinetics and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.